International BEAT-PCD consensus statement for infection prevention and control for primary ciliary dyskinesia in collaboration with ERN-LUNG PCD Core Network and patient representatives.

Marthin, June K; Lucas, Jane S; Boon, Mieke; Casaulta, Carmen; Crowley, Suzanne; Destouches, Damien M S; Eber, Ernst; Escribano, Amparo; Haarman, Eric; Hogg, Claire; Maitre, Bernard; Marsh, Gemma; Martinu, Vendula; Moreno-Galdó, Antonio; Mussaffi, Huda; Omran, Heymut; Pohunek, Petr; Rindlisbacher, Bernhard; Robinson, Phil; Snijders, Deborah; ... (2021). International BEAT-PCD consensus statement for infection prevention and control for primary ciliary dyskinesia in collaboration with ERN-LUNG PCD Core Network and patient representatives. ERJ Open Research, 7(3) European Respiratory Society 10.1183/23120541.00301-2021

Preview

Text International_BEAT-PCD_consensus_statement_for_infection_prevention_and_control_for_primary_ciliary_dyskinesia_in_collaboration_with_ERN-LUNG_PCD_Core_Network_and_patient_representatives.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (684kB) | Preview

Introduction

In primary ciliary dyskinesia (PCD) impaired mucociliary clearance leads to recurrent airway infections and progressive lung destruction, and concern over chronic airway infection and patient-to-patient transmission is considerable. So far, there has been no defined consensus on how to control infection across centres caring for patients with PCD. Within the BEAT-PCD network, COST Action and ERS CRC together with the ERN-Lung PCD core a first initiative has now been taken towards creating such a consensus statement.

Methods

A multidisciplinary international PCD expert panel was set up to create a consensus statement for infection prevention and control (IP&C) for PCD, covering diagnostic microbiology, infection prevention for specific pathogens considered indicated for treatment and segregation aspects. Using a modified Delphi process, consensus to a statement demanded at least 80% agreement within the PCD expert panel group. Patient organisation representatives were involved throughout the process.

Results

We present a consensus statement on 20 IP&C statements for PCD including suggested actions for microbiological identification, indications for treatment of Pseudomonas aeruginosa, Burkholderia cepacia and nontuberculous mycobacteria and suggested segregation aspects aimed to minimise patient-to-patient transmission of infections whether in-hospital, in PCD clinics or wards, or out of hospital at meetings between people with PCD. The statement also includes segregation aspects adapted to the current coronavirus disease 2019 (COVID-19) pandemic.

Conclusion

The first ever international consensus statement on IP&C intended specifically for PCD is presented and is targeted at clinicians managing paediatric and adult patients with PCD, microbiologists, patient organisations and not least the patients and their families.

Interest & Impact

Downloads

58 since deposited on 16 Sep 2021
39 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item